Cellular immunotherapies
CytoMed creates allogenic, off-the-shelf cellular immunotherapies for treating human cancers, including liquid and solid tumors.
Source: LinkedIn company description · Retrieved October 13, 2026
CytoMed Therapeutics is a biopharmaceutical company focused on using its licensed proprietary technologies to create allogenic, off-the-shelf cellular immunotherapies.
Incorporated in 2018, CytoMed Therapeutics was spun off from Singapore’s Agency for Science, Technology and Research (A*STAR). Its technology development is informed by CAR-T’s clinical success in hematological malignancies and challenges applying the approach to solid tumors.
Based on the company’s public LinkedIn information, supplied through RevenueBase.
CytoMed creates allogenic, off-the-shelf cellular immunotherapies for treating human cancers, including liquid and solid tumors.
Source: LinkedIn company description · Retrieved October 13, 2026
Supported appearances on published RevenueBase lists, including available memberships beyond displayed rankings.
Positions describe ordering within each source list. See how lists are built ↗
Embeddable award for your website
Snapshot: October 8, 2026
RevenueBase prepared this profile from the company’s public LinkedIn information and RevenueBase company data. These source records were retrieved on October 13, 2026. AI helped summarize these sources, with a separate automated check against the source text completed on November 4, 2026. Directory positions use company-contact counts from separate saved list snapshots dated October 8, 2026. How the company lists are built.
Share a correction, your relationship to the company, and supporting sources. Requests are reviewed before changes are published.
Explore more companies by name, headquarters and business focus.